A year later, these results were confirmed in another small study by Sato et al. In 40 T2DM patients with CAD, a 24-week therapy with dapagliflozin compared to conventional therapy, caused a significant decrease in EAT volume evaluated by CCT, with a significant positive correlation with circulating TNF-α level [132]. This evidence concerns the gene TNF and type 2 diabetes mellitus.